MBX

MBX Biosciences, Inc. Common Stock$35.39-1.86 (-4.99%)

Prev Close$37.25·MCap$1.04B·P/E—·Vol1.94M·Yield—

▲

Buys (12M)

$13.06M

▼

Sells (12M)

$2.71M

◆

Net Activity

Net Buyer

$10.35M

●

Active Insiders

last 12 mo

Over the past 12 months, insider activity at MBX Biosciences, Inc. Common Stock (MBX) has been dominated by buying, with 4 insider purchases totaling $13.06M and 3 insider sales totaling $2.71M. The most recent insider transaction was by Azoulay Salomon (officer: Chief Medical Officer), who sold $2.69M worth of shares on May 11, 2026. MBX Biosciences, Inc. Common Stock operates in the Healthcare sector, within the Biotechnology industry, with a market cap of $1.04B.

MBX Insider Trading Activity

Date	Insider	Role	Type	Shares	Avg Price	Value	Shares After
May 11, 2026	Azoulay Salomon	officer: Chief Medical Officer	Sell	70,003	$38.36	$2.69M	14,769-83%
May 8, 2026	Azoulay Salomon	officer: Chief Medical Officer	Sell	231	$29.54	$6.8K	14,769
May 8, 2026	Hawryluk P. Kent	director, officer: President & CEO	Sell	607	$29.54	$17.9K	727,667
Mar 16, 2026	Hawryluk P. Kent	director, officer: President & CEO	Buy	18,500	$28.41	$525.7K	486,777
Oct 20, 2025	Hawryluk P. Kent	President & CEO	Buy	20,000	$13.64	$272.8K	0
Oct 17, 2025	Hoerter Steven L.	Director	Buy	20,000	$13.25	$265.0K	0
Sep 26, 2025	Heron Patrick J	Director	Buy	666,666	$18.00	$12.00M2.0% OS	0
Apr 8, 2025	Pescovitz Ora H.	Director	Buy	7,693	$5.89	$45.3K	0
Feb 19, 2025	GORDON CARL L	Director	Buy	190,672	$10.60	$2.02M0.6% OS	3,255,000
Feb 5, 2025	Hawryluk P. Kent	President & CEO	Buy	50,000	$10.69	$534.5K	448,277
Sep 17, 2024	Aynechi Tiba		Buy	750,000	$16.00	$12.00M2.2% OS	2,136,335+54%
Sep 17, 2024	Frazier Life Sciences X, L.P.		Buy	625,000	$16.00	$10.00M1.9% OS	4,552,774
Sep 17, 2024	Mathers Edward T		Buy	500,000	$16.00	$8.00M1.5% OS	3,614,486
Sep 17, 2024	ORBIMED ADVISORS LLC		Buy	750,000	$16.00	$12.00M2.2% OS	3,158,428+31%

MBX Insider Buying Activity

The following table shows recent insider purchases of MBX Biosciences, Inc. Common Stock (MBX) stock reported via SEC Form 4 filings.

Date	Insider	Role	Type	Shares	Avg Price	Value	Shares After
Mar 16, 2026	Hawryluk P. Kent	director, officer: President & CEO	Buy	18,500	$28.41	$525.7K	486,777
Oct 20, 2025	Hawryluk P. Kent	President & CEO	Buy	20,000	$13.64	$272.8K	0
Oct 17, 2025	Hoerter Steven L.	Director	Buy	20,000	$13.25	$265.0K	0
Sep 26, 2025	Heron Patrick J	Director	Buy	666,666	$18.00	$12.00M2.0% OS	0
Apr 8, 2025	Pescovitz Ora H.	Director	Buy	7,693	$5.89	$45.3K	0
Feb 19, 2025	GORDON CARL L	Director	Buy	190,672	$10.60	$2.02M0.6% OS	3,255,000
Feb 5, 2025	Hawryluk P. Kent	President & CEO	Buy	50,000	$10.69	$534.5K	448,277
Sep 17, 2024	Aynechi Tiba		Buy	750,000	$16.00	$12.00M2.2% OS	2,136,335+54%
Sep 17, 2024	Frazier Life Sciences X, L.P.		Buy	625,000	$16.00	$10.00M1.9% OS	4,552,774
Sep 17, 2024	Mathers Edward T		Buy	500,000	$16.00	$8.00M1.5% OS	3,614,486
Sep 17, 2024	ORBIMED ADVISORS LLC		Buy	750,000	$16.00	$12.00M2.2% OS	3,158,428+31%

MBX Insider Selling Activity

The following table shows recent insider sales of MBX Biosciences, Inc. Common Stock (MBX) stock reported via SEC Form 4 filings.

Date	Insider	Role	Type	Shares	Avg Price	Value	Shares After
May 11, 2026	Azoulay Salomon	officer: Chief Medical Officer	Sell	70,003	$38.36	$2.69M	14,769-83%
May 8, 2026	Azoulay Salomon	officer: Chief Medical Officer	Sell	231	$29.54	$6.8K	14,769
May 8, 2026	Hawryluk P. Kent	director, officer: President & CEO	Sell	607	$29.54	$17.9K	727,667